This prospective, double-masked study randomized 286 dry eye patients to receive a single drop of 1% or 3% diquafosol or placebo ophthalmic solutions, six times a day for six weeks. Diquafosol, a P2Y2 receptor agonist, promotes secretion of aqueous tears and mucins on the ocular surface. At four weeks, fluorescein corneal staining scores, rose bengal corneal and conjunctival staining scores, and dry eye syndrome scores improved significantly with both dosages of diquafosol compared to placebo. A study in this month’s British Journal of  Ophthalmology showed diquafosol exhibited similar efficacy to  sodium hyaluronate in improving fluorescein staining scores of dry eye patients. However, diquafosol showed superior efficacy in improving rose bengal staining scores. Ophthalmology, October 2012